ValuEngine cut shares of Quidel (NASDAQ:QDEL) from a hold rating to a sell rating in a research report released on Monday morning, ValuEngine reports.

A number of other equities research analysts have also weighed in on QDEL. Barclays reaffirmed a buy rating and set a $304.00 price target on shares of Adobe in a report on Monday, March 18th. BidaskClub raised shares of Zumiez from a sell rating to a hold rating in a report on Saturday, June 22nd. Canaccord Genuity reaffirmed a speculative buy rating and set a GBX 70 ($0.91) price target on shares of Bacanora Lithium in a report on Monday, July 1st. Raymond James reaffirmed an average rating and set a $23.00 price target on shares of in a report on Monday, April 15th. Finally, Zacks Investment Research raised shares of HAYS PLC/ADR from a sell rating to a hold rating in a report on Tuesday, June 18th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $71.17.

Shares of Quidel stock traded up $0.55 during trading hours on Monday, hitting $57.73. The company’s stock had a trading volume of 91,200 shares, compared to its average volume of 212,204. Quidel has a 1-year low of $44.27 and a 1-year high of $77.63. The firm has a fifty day moving average price of $57.13. The firm has a market cap of $2.29 billion, a P/E ratio of 20.47, a PEG ratio of 0.86 and a beta of 1.36. The company has a quick ratio of 0.91, a current ratio of 1.33 and a debt-to-equity ratio of 0.25.

Quidel (NASDAQ:QDEL) last released its quarterly earnings results on Wednesday, May 8th. The company reported $0.84 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.98 by ($0.14). The firm had revenue of $148.00 million for the quarter, compared to analyst estimates of $157.61 million. Quidel had a net margin of 12.98% and a return on equity of 25.33%. Quidel’s revenue for the quarter was down 12.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.29 earnings per share. Analysts anticipate that Quidel will post 2.72 EPS for the current year.

In other Quidel news, VP Edward Keith Russell sold 13,000 shares of the firm’s stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $57.16, for a total transaction of $743,080.00. Following the completion of the transaction, the vice president now directly owns 18,401 shares of the company’s stock, valued at approximately $1,051,801.16. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Kenneth F. Buechler sold 2,002 shares of the firm’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $60.58, for a total transaction of $121,281.16. Following the transaction, the director now directly owns 49,771 shares of the company’s stock, valued at $3,015,127.18. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 69,963 shares of company stock valued at $4,018,580. Company insiders own 14.10% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Strs Ohio acquired a new position in Quidel during the 1st quarter worth $58,000. Huntington National Bank acquired a new position in Quidel during the 1st quarter worth $73,000. NumerixS Investment Technologies Inc grew its holdings in Quidel by 178.3% during the 1st quarter. NumerixS Investment Technologies Inc now owns 1,400 shares of the company’s stock worth $90,000 after acquiring an additional 897 shares in the last quarter. Paloma Partners Management Co acquired a new position in Quidel during the 4th quarter worth $212,000. Finally, Amalgamated Bank acquired a new position in Quidel during the 4th quarter worth $242,000. 91.40% of the stock is owned by institutional investors.

Quidel Company Profile

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.

Recommended Story: How much can an individual set aside as a catch-up contribution?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Quidel (NASDAQ:QDEL)

Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.